YK-029A is an orally active inhibitor of mutant EGFR，targeting to both the T790M mutations (EGFRT790M) and exon 20 insertion of EGFR (EGFRex20ins). YK-029A exhibits significant antitumor activity，and results tumor regression in EGFRex20ins-driven PDX models.
References:
[1]. Liu B, et al. Discovery of YK-029A, a novel mutant EGFR inhibitor targeting both T790M and exon 20 insertion mutations, as a treatment for NSCLC. Eur J Med Chem. 2023 Oct 5;258:115590.